|
HRSA Advancing Precision Medicine (HRSA APM)
|
Other
|
HRSA
|
OD/AoU
|
In 2018, HRSA awarded $456K to 40 HRSA FQHCs to work on engagement activities and EHR sharing for AoU. The period of performance ran through September 2020 with some FQHCs operating on a No Cost Extension through December 2020. NIH continues to meet with HRSA monthly to discuss the potential for future opportunities to add FQHCs to the All of Us Research Program. NIH AoURP and HRSA collaborated on a workbench presentation to HRSA and all FQHCs in winter 2021. Another presentation is planned for Spring 2022.
|
|
Human skin sensitization data set
|
Research Initiative
|
FDA
|
NIEHS
|
NICEATM and collaborators collected data for over 2,300 human predictive patch tests from more than 1,700 publications.
|
|
Human Specimen Collection to Support Basic and Clinical Research
|
Research Initiative
|
FDA
|
NHLBI
|
Human Specimen Collection to Support Basic and Clinical Research
|
|
I-Corps @ NIH
|
Training Initiative
|
CDC
|
NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS
|
The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. Through the 8.5 week program training, companies are expected to conduct 100 interviews to gather stakeholder feedback on the product. So far, more than 100 companies have gone through the program. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Currently NCI is reviewing the application for the second cohort of 2022. From fiscal year 2023, the management of the program will be transferred from the NCI to NIH.
|
|
IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing
|
Other
|
FDA
|
NIAID
|
This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID.
|
|
ICCFASD SBI Working Group for Pregnant and Postpartum People (ISBI-WG) (ISBI)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ASPE, CDC, CMS, IHS, HRSA, SAMHSA
|
NIAAA, NIDA
|
This is a special interest working group formed and led by the ICCFASD. The objectives of the ISBI working group are to exchange information and resources, identify gaps and opportunities for improved implementation and research, and expand collaboration and partnerships between federal agencies. The group includes representatives from the ICCFASD and other federal agencies.
|
|
ICCFASD Strategic Planning Working Group (ISP)
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, CDC, CMS, HRSA, SAMHSA
|
NIAAA, NICHD
|
The ICCFASD Strategic Planning Working Group was formed to review the ICCFASD FY06-10 Strategic Plan and make recommendations to the ICCFASD on ICCFASD strategic planning to make the most impact in the next several years. The ICCFASD Strategic Planning Working Group includes representatives from a variety of ICCFASD member agencies. Continued engagement with communities is essential to the ICCFASD. Input has been sought from a range of community partners (e.g., researchers, practitioners, individuals with lived experiences) to ensure that the ICCFASD collaborative partnership and its priorities and objectives address the needs of persons affected by Fetal Alcohol Spectrum Disorders (FASD) and their families and prevention of prenatal alcohol exposure in children.
|
|
ICCVAM Ecotoxicology Workgroup (EcoWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIEHS
|
ICCVAM workgroup that provides expertise in identifying and evaluating in vitro and in silico methods to identify ecological and environmental hazards.
|
|
ICCVAM In Vitro to In Vivo Extrapolation Workgroup (IVIVE-WG)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, FDA
|
NIEHS, NLM
|
ICCVAM workgroup established to catalog and evaluate currently available IVIVE approaches, to determine their suitability for specific research or regulatory purposes, and to assess whether additional tools or models are needed.
|
|
ICCVAM Metrics Workgroup (MWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIEHS, OD
|
ICCVAM workgroup established to develop objectives and determine how agencies can best address the recommendations in the 2019 GAO report, "Animal Use in Research"
|